碎石手术费用价格表重庆肾结石一般怎么治重庆,胆囊结石发炎怎么治疗最好的方法重庆,输尿管结石怎样可以最快排出来重庆,重庆哪个医院可以体外碎石,重庆膀胱结石2cm最佳治疗方案,肾结石断根的土方子重庆,重庆女肾结石有什么症状和早期症状

UNITED NATIONS, Sept. 19 (Xinhua) -- As the UN on Monday pursued the world's top killer -- non-communicable diseases (NCDs) -- a leading doctor from the World Health Organization (WHO) called for preventative measures on such chronic diseases to be placed higher on the international agenda."It's not a choice of dealing with it or not, it's an absolute fundamental imperative for development," said Dr. Douglas Bettcher, WHO's director for the Tobacco Free Initiative, told Xinhua in a recent telephone interview.With NCDs already claiming 36 million lives a year -- nearly 100,000 people a day -- the UN Geneva-based health agency, WHO warns that deaths from chronic diseases will continue to climb even faster, amounting to 52 million deaths by 2030.As world leaders on Monday kicked off a two-day high-level meeting to enact a roadmap to attack diseases like cancer, diabetes, heart and lung diseases, it is hoped that the summit on NCDs, which is being called a "once in a generation opportunity," moves to become a "worldwide priority," Bettcher said.Marking the second time in its history that the United Nations General Assembly has ever put a global disease on the table, health experts and world leaders from 193 nations met to avert what the UN has declared a "public health emergency in slow motion. ""It's a make it or break it time for moving forward this very important agenda at this time of global financial crisis," said Bettcher.Calling NCDs the top global killer "by a long shot," Bettcher attributed such rises in deaths partly to the aging of the world's population, rapid urbanization and increased exposure to risk factors, particularly in low-and middle-income countries."This is a landmark meeting," said UN Secretary-General Ban Ki- moon at the opening of the unprecedented meeting. "Three out of every five people on earth die from the diseases that we gather here to address."The last time the UN looked at a health issue under the global microscope on such a high-level was almost a decade ago.

YANGON, July 10 (Xinhua) -- Myanmar is projecting to build the first-ever liver transplant hospital in line with the international standard, the local weekly Voice reported Sunday.With the technological help of the Changi General Hospital of Singapore, a 40-million-U.S dollar worth private hospital has started building since late last month.The hospital will offer services for the patients living with heart and kidney diseases and for protection from being affected Methicillin-Resistant Staphylococcus Aureus (MRSA), the report said.In Myanmar, liver transplant will cost about 20 million Kyats ( 25,000 U.S. dollars), lesser than other countries, the report added.Myanmar experts carried out successful liver-transplant operation in 2004 for the first time and in 2009 for the second time.

BEIJING, Sept. 26 (Xinhua) -- Nobel laureates on Monday cast doubt on a European experiment that purportedly demonstrated the ability of neutrinos to move faster than the speed of light.They made the remarks in Beijing prior to a forum for Nobel laureates."I'm willing to bet money that it's not correct," said Professor George Smoot III, winner of the 2006 Nobel Prize in Physics and a professor at University of California, Berkeley, referring to an experiment result claiming that particles apparently travel faster than light.The experiment reported an anomaly in the flight time of neutrinos, or electrically neutral subatomic particles, from the European Center for Nuclear Research (CERN) in Switzerland to a laboratory located 730 kilometers away in Italy.Particles were clocked transmitting at a speed of 300,006 kilometers per second, about 60 nanoseconds faster than the speed of light.Smoot said that the claims "did not make sense" and should be verified by other scientists first."There are many distortions in physics. You have to have a very high standard to see if something is truly correct," he said.The unverified findings were published on Sept. 22 in the scientific journal Nature. European researchers working in a team called OPERA (Oscillation Project with Emulsion-Racking Apparatus) projected masses of neutrinos from CERN and then collected the particles using a massive detector in Gran Sasso, south of Rome.Other scientists, as well as the OPERA team themselves, have voiced doubts regarding the experiment's results.The findings, CERN claims, could pose far-reaching potential consequences once verified.If correct, the results would bring Einstein's theory of special relativity into question. Under this theory, a physical object cannot travel faster than the speed of light in a vacuum."If really it is right, we have to rethink everything we know," said Chris Llewellyn Smith, former director of CERN.Smith claimed the unprecedented discovery was too exceptional to find proof."If somebody makes a very exceptional claim, then very exceptional proof would need to come from another experiment, saying the same thing. But we don't have the other thing," Smith said.Carlos Rubbia, a Nobel Laureate who won the prize for physics in 1984, is in charge of a team of more than 100 scientists at CERN."What it is pretending to find, in my view, is unbelievably surprising," Rubbia said."Frankly, I have the feeling that this is still a very experimental consideration," Rubbia said.He also believes that revealing the findings to the public was a mistake as it remained an experimental process and no conclusion could be drawn without the results of another experiment.Despite the possibility of verification, Einstein's special theory of relativity will remain valid."I will be very, very surprised that, at last, Einstein will not be the winner," Rubbia said.To achieve a breakthrough, Rubbia has urged for more joint cooperation on verifying the test results. International cooperation on this issue "is a must.""It requires coordination from all nations," said Rubbia.The 2011 Nobel Laureates Beijing Forum will be held from Sept. 28 to 30 under a theme of "innovation and development."

SINGAPORE, Sept. 7 (Xinhua) -- Singapore scientists have found possible new ways to treat a type of aggressive breast cancer that is unresponsive to current forms of treatment, local broadcaster Channel NewsAsia reported on Wednesday.The team of scientists at the Genome Institute of Singapore ( GIS) and National University of Singapore (NUS), led by GIS senior group leader Qiang Yu, found that the enzyme EZH2 acts by inhibiting genes that stop the growth of tumors in the body.The insights could open the door to developing more effective treatment for fast spreading breast cancers, especially the estrogen receptor-negative breast cancer that is common all over the world.It was also found that through EZH2, cancer is promoted in the body by activating specific genes that impact breast cancer progression and cancer stem cell self-renewal.Yu said the new understanding on how EZH2 works as a cancer- causing gene in breast cancer has important therapeutic implication."The results suggest that small molecule drugs that block enzyme activity of EZH2 may not work for cancers caused by EZH2's activation genes," Yu said.Currently pharmaceutical companies have been developing drugs only to the block EZH2 enzyme activity so that tumor suppressers can perform their protective role in blocking cancer growth.Researchers said the next step would be to develop biomarkers to identify tumors with EZH2.This step would enable better treatment methods, with one of options being the development of therapies that shut down EZH2 completely and not just inhibit its enzymatic function.The findings have been published on the journal Molecular Cell.

BEIJING, August 4 (Xinhuanet) -- Medtronic Inc. is giving Yale University a 2.5 million U.S. dollar grant to review the safety and effectiveness of its controversial spine treatment called Infuse Bone Graft, according to The Wall Street Journals Thursday.Under terms of the pact, the company will release to Yale and eventually the public what participants described as an unprecedented amount of clinical trial and other data. The university will select two research teams from other organizations to perform separate analyses of the data.The announcement comes in the wake of a paper in June in the Spine Journal. The paper revealed that several clinical studies of Infuse, conducted by surgeons with strong economic ties to Medtronic, failed to report serious complications that arose in the trials. The critical paper also found that many of the studies were designed in ways in favor of Infuse over a treatment given to a control group.Medtronic disputes some of the findings and is conducting an internal investigation of the matter.Infuse accounts for about 700 million dollars in annual sales for Medtronic. The product is under investigation by the Senate Finance Committee over the role payments to physicians who may have played how studies were reported.